Test Price
900 AED✅ Home Collection Available
HLA-A2 (A*02) Typing Test in UAE | 900 AED | 2026 DHA Guidelines
تحليل مستضد الكريات البيضاء البشرية HLA-A2 (A*02) في الإمارات | 900 درهم | معتمد من هيئة الصحة بدبي 2026
Executive Summary
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Reverse SSOP-Luminex molecular methodology delivering allele-level resolution for HLA-A*02 subtyping.
- ✓Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain transport. VIP Mobile Phlebotomy available 8 AM – 11 PM across all Emirates, with refrigerated specimen handling to preserve lymphocyte viability.
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed clinicians, correlating HLA-A2 status with disease susceptibility profiles and pharmacogenetic implications.
- ✓Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. Pre-approval coordination with major UAE insurers.
الملخص التنفيذي
يقدم هذا التحليل الجزيئي المتقدم تحديد أليل مستضد الكريات البيضاء البشرية HLA-A*02 بدقة عالية باستخدام تقنية reverse SSOP-Luminex المعتمدة وفق معايير الآيزو 9001:2015. يُستخدم هذا الفحص في تقييم القابلية الوراثية للأمراض والاستجابة الدوائية تحت إشراف أطباء مرخصين من هيئة الصحة بدبي، مع خدمة سحب منزلي مبرد ونقل آمن للعينة لضمان سلامة الخلايا الليمفاوية. السعر: 900 درهم إماراتي. مدة النتيجة: 10-12 يوم عمل.
Overview
The HLA-A2 (A*02) Typing Test is a high-resolution molecular assay that identifies the presence of the HLA-A*02 allele — the most prevalent human leukocyte antigen (HLA) Class I allele globally, with significant implications in autoimmune disease susceptibility, drug hypersensitivity reactions, and neuropsychiatric disorder predisposition. This test employs Reverse Sequence-Specific Oligonucleotide Probe (rSSOP) technology on the Luminex bead-based platform, delivering allele-level genotyping essential for neurologists, psychiatrists, and primary care physicians managing patients with suspected HLA-linked conditions.
يُعد تحليل HLA-A2 من الفحوصات الجزيئية الأساسية في الطب الدقيق، حيث يوفر معلومات حاسمة عن القابلية الوراثية لأمراض المناعة الذاتية والاضطرابات العصبية والنفسية، مما يساعد الأطباء في توجيه القرارات العلاجية وتقييم مخاطر التفاعلات الدوائية الضارة.
| Feature | Our HLA-A2 Test (rSSOP-Luminex) | Closest Alternative (Serological HLA Typing) |
|---|---|---|
| Precision | Allele-Level Resolution — distinguishes A*02:01 from A*02:05 and other subtypes | Broad antigen-level detection only; cannot differentiate subtypes or confirm allele specificity |
| Methodology | Reverse SSOP — Luminex Bead Array — multiplexed, high-throughput, CE-marked | Complement-Dependent Cytotoxicity (CDC) — low resolution, labour-intensive, subjective readout |
| Clinical Utility | Disease Association & Pharmacogenetics — robust for MS, narcolepsy, drug hypersensitivity | Primarily transplant compatibility; limited disease-association sensitivity |
| Turnaround Time | 10–12 Days | 7–14 Days (variable, lab-dependent) |
| Cost (UAE) | 900 AED — all-inclusive with home collection | 600–800 AED (hospital phlebotomy only; additional collection fee may apply) |
Physician Insight & Safety Protocol
Clinical Note from Dr. Prabhakar Reddy — DHA License: 61713011
"The HLA-A2 allele is not merely a laboratory value — it is a clinically actionable biomarker that must be interpreted within the complete landscape of the patient's history, symptoms, and concurrent medications. I strongly advise that no therapeutic decision be made solely on the basis of a positive or negative HLA-A2 result. Clinical correlation with neurological examination, psychiatric evaluation, and relevant imaging or serological markers is essential. A positive HLA-A2 finding may support — but never replace — a comprehensive differential diagnosis."
Critical Medication Advisory: Do not discontinue, adjust, or substitute any prescribed medication — including but not limited to immunomodulators, antiepileptics, antipsychotics, or corticosteroids — without explicit consultation with your treating physician. HLA-A2 genotyping is a susceptibility assessment tool and does not independently dictate pharmacotherapy changes.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection:
- Active febrile illness (temperature >38.5°C) — reschedule after clinical resolution.
- Recent blood transfusion (<90 days) — may confound lymphocyte genotyping accuracy.
- Known cold agglutinin disease — coordinate with laboratory for special handling protocol.
- Severe thrombocytopenia (platelets <30,000/µL) — venipuncture risk; requires physician clearance.
- Inability to provide informed consent (see UAE CDS Law 2026 for minors — guardian consent mandatory).
Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden onset severe headache with vision changes or focal neurological deficit.
- Acute confusional state, psychosis, or catatonia — psychiatric emergency.
- Signs of severe cutaneous adverse reaction (SCAR): extensive rash, blistering, mucosal involvement, fever.
- Unexplained seizure activity or loss of consciousness.
- Any suspected anaphylactic reaction — call UAE Emergency (998) immediately.
This test is a diagnostic adjunct, not an emergency screening tool. For life-threatening symptoms, proceed directly to the nearest DHA-licensed emergency department.
Patient FAQ & Clinical Guidance
Q1: What exactly does the HLA-A2 test detect, and why has my physician ordered it?
Snippet: The HLA-A2 test detects the presence of the HLA-A*02 allele — a specific genetic variant on chromosome 6 that encodes a cell-surface protein involved in immune recognition, disease susceptibility, and drug-response pathways.
This test is frequently ordered by neurologists evaluating patients for multiple sclerosis or narcolepsy, by psychiatrists assessing pharmacogenetic risks prior to initiating certain psychotropic medications, or by general physicians investigating unexplained autoimmune symptoms. The result helps your doctor understand whether your immune system carries this genetic marker, which is present in approximately 40–50% of Caucasian populations and varies across ethnic groups. It does not diagnose any disease independently — it provides one piece of a larger diagnostic puzzle that your physician will assemble alongside your clinical history, physical examination, and other laboratory findings.
Q2: How should I prepare for the blood draw, and what happens to my specimen after collection?
Snippet: No fasting, dietary restriction, or medication adjustment is required — simply present for your home collection appointment with your Emirates ID and insurance card ready.
Our DHA-licensed phlebotomist will collect 4 mL of whole blood in a Lavender Top (EDTA) tube or, alternatively, 6 mL in a Yellow Top (ACD) tube. The specimen is immediately placed in a validated cold-chain transport container (2–8°C), never frozen, and delivered to our ISO-certified molecular diagnostics laboratory within hours. Freezing would lyse the lymphocytes and compromise DNA integrity, so strict temperature control is maintained throughout logistics. Your DNA is extracted, amplified, and hybridized against sequence-specific oligonucleotide probes on the Luminex platform, producing an allele-level genotype report reviewed by a senior clinical scientist before release.
Q3: What does a positive HLA-A2 result mean for my health and treatment plan?
Snippet: A positive HLA-A2 result indicates genetic susceptibility to certain autoimmune and neurological conditions — it is a risk marker, not a diagnosis, and must always be correlated clinically.
A positive finding means your cells express the HLA-A2 antigen. In the context of specific clinical presentations, this may strengthen the likelihood of conditions such as multiple sclerosis (where HLA-A2 has been associated with disease course modulation), narcolepsy (HLA-A2 interaction with HLA-DQB1*06:02), or certain drug hypersensitivity syndromes. However, many healthy individuals carry HLA-A2 without ever developing disease. Your treating physician will weigh this result alongside your symptom profile, imaging studies, and other biomarkers. Therapeutic decisions — including initiation, continuation, or cessation of immunomodulatory therapy — require holistic clinical judgment and should never be based on genotype alone.
النتيجة الإيجابية لتحليل HLA-A2 تشير إلى وجود العامل الوراثي المرتبط بزيادة القابلية للإصابة ببعض أمراض المناعة الذاتية والاضطرابات العصبية، ولكنها ليست تشخيصاً قاطعاً بحد ذاتها. يجب على الطبيب المعالج ربط هذه النتيجة بالفحص السريري الشامل والتاريخ المرضي والفحوصات التكميلية الأخرى قبل اتخاذ أي قرار علاجي. العديد من الأفراد الأصحاء يحملون هذا الأليل دون ظهور أي أعراض مرضية.
Regulatory Compliance: This laboratory service operates under UAE Federal Decree-Law No. 41 of 2024 (Art. 87), the UAE CDS Law 2026 (Minors Consent Provisions), and the UAE Personal Data Protection Law (PDPL). All patient data is processed in compliance with ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and DHA Facility License No. 9834453. Methodology: Reverse Sequence-Specific Oligonucleotide Probe (rSSOP) — Luminex Bead Array Platform. Sample requirement: 4 mL (3 mL minimum) whole blood in Lavender Top (EDTA) tube OR 6 mL (3 mL minimum) whole blood in Yellow Top (ACD) tube. Ship refrigerated at 2–8°C. DO NOT FREEZE. Pre- information: No special preparation required. Turnaround Time: 10–12 working days. Price: 900 AED inclusive of home collection.
📞 Support & WhatsApp: +971 54 548 8731 📧 DHA Facility License: 9834453 🏥 Reviewed by: Dr. Prabhakar Reddy, DHA 61713011
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians